Premium
The use of radionuclides in the detection of bone metastases
Author(s) -
Verdon Thomas A.,
Yano Yukio,
Anger Hal O.
Publication year - 1971
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930030613
Subject(s) - medicine , radionuclide imaging , bone imaging , nuclear medicine , radionuclide , radiology , strontium , radionuclide therapy , positron emission tomography , medical physics , physics , quantum mechanics , nuclear physics
Abstract Bone imaging is a valuable procedure in the evaluation of patients suspected of having metastatic disease to bone. Its use has been well established in many clinical studies. Several radionuclides are available that can detect the presence of metastatic disease before X‐ray changes occur. Because other nonmalignant conditions may produce positive bone scans, the procedure must be used in conjunction with the appropriate X‐ray and other diagnostic studies. Fluorine‐18 approaches the ideal bone‐imaging radionuclide. As it becomes more available commercially, fluorine‐18 will probably replace strontium‐85 as the main radionuclide for bone imaging. Although fluorine‐18 bone imaging with a whole body scanner and the positron camera affords a most optimal combination, the use of strontium‐85 with conventional imaging equipment provides the physician with important clinical information that cannot be obtained by other studies.